$QNTM News

Quantum BioPharma (QNTM) Featured in Men's Fitness Article Examining Unbuzzd Clinical Trial Results

World Renowned Law Firm Grant & Eisenhofer Appointed Lead Counsel In Newly Consolidated Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares

Quantum BioPharma (QNTM) Enlists Thermo Fisher's Clinical Research Business to Launch Phase 2 Lucid-MS Trial

Quantum BioPharma (QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 Trial

Quantum BioPharma (QNTM) Receives FDA Green Light to Move Lucid-MS Into Phase 2 Testing

Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO

Quantum BioPharma’s Licensee Unbuzzd Wellness Announces Appointment Of Michael Zapolin As CEO

Quantum BioPharma (QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments

Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target

Quantum BioPharma (QNTM) to Present at 3rd Annual ArcStone-Kingswood Growth Summit

Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto

Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto

Quantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment

Reported Earlier, Quantum BioPharma Plans To Leave Canadian Exchange While Keeping Nasdaq Listing

Rodman & Renshaw Initiates Coverage On Quantum BioPharma with Buy Rating, Announces Price Target of $8

Quantum Biopharma Provides Corporate Update

Quantum BioPharma (QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm Evolves

Quantum BioPharma (QNTM) Reports Lower Q2 Expenses, Advances Lucid-MS Into Phase 2

Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial

Quantum BioPharma (QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple Sclerosis